DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.

Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.

In a Hirschsprung disease mouse model, diet shifted gut microbes and inflammation, with a 3-fold survival difference between standard diets.

A national claims analysis found 16.8% of pediatric GLP-1 users developed a nutritional deficiency within a year, most often vitamin D, while few received nutritional counseling.

Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.

A Bifidobacterium-based synbiotic was well tolerated and increased colonization of administered strains in infants and toddlers.

Pediatricians can help teen athletes navigate sports supplements by prioritizing nutrition and identifying products to support, limit, or avoid.

Semaglutide plus lifestyle changes moved 40.4% of children below the obesity threshold at 68 weeks in the phase 3 STEP Young trial.